New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
09:27 EDTGALT, DATA, BYD, YRCW, ARRY, GPRO, PXLW, SPWR, WWWW, HIL, SGMS, PG, ARNA, BYI, EXPE, LNKDOn The Fly: Pre-market Movers
HIGHER: Procter & Gamble (PG), up 2.2% after core EPS beat expectations, company announces plans to trim portfolio to 70-80 "core" brands... Expedia (EXPE), up 3.5% after upgraded at Raymond James following better than expected Q2 earnings results... Bally Technologies (BYI), up 31% after Scientific Games (SGMS) to acquire the company for $83.30 per share, or $5.1B. Scientific Games is up 13% after the news... Array BioPharma (ARRY), up 6% after receiving orphan status for ovarian cancer treatment... Tableau (DATA), up 4.5% after upgraded at Mizuho after better than expected Q2 earnings results. UP AFTER EARNINGS: LinkedIn (LNKD), up 8.6%... Arena Pharmaceuticals (ARNA), up 3.5%. DOWN AFTER EARNINGS: GoPro (GPRO), down 10.6%... SunPower (SPWR), down 3.1%... Pixelworks (PXLW), down 16.8%... YRC Worldwide (YRCW), up 15.8%. LOWER: Web.com (WWWW), down 25% after reporting second quarter results and acquiring U.K. online directory company Scoot... Hill International (HIL), down 12.9% after 8.5M share secondary offering priced at $4.25... Boyd Gaming (BYD), down 7.4% after downgraded at Credit Suisse following lower than expected Q2 earnings results... Galectin Therapeutics (GALT), down 4% after downgraded at Aegis... Biota (BOTA), down 33% after IGLOO did not achieve significant reduction in time to alleviation.
News For PG;LNKD;BYI;SGMS;EXPE;ARNA;HIL;WWWW;GPRO;BYD;SPWR;ARRY;DATA;PXLW;YRCW;GALT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 19, 2015
08:23 EDTDATATableau the best way to play Big Data for the 'mass market,' says UBS
UBS believes Tableau Software is the best way to play big data for the "mass market" and sees several upcoming catalysts for the stock. The firm cited European growth, new products, and the kickoff of its global system integration. UBS reiterated its Buy rating and $109 price target on Tableau shares.
08:03 EDTPGInter Parfums unit to acquire Procter & Gamble's Rochas brand for $108M
Inter Parfums (IPAR) announced that its majority owned Paris-based subsidiary, Interparfums S.A. has entered into an agreement with The Procter & Gamble Company (PG) to acquire the Rochas brand. This transaction will cover all brand names and registered trademarks for Rochas, mainly for class 3 cosmetics and class 25 fashion. This acquisition will be payable in cash on the closing date for $108M and financed entirely through a medium term loan. This transaction is expected to be completed within the first half of 2015, subject to customary closing conditions.
06:55 EDTLNKDCertain news agencies form advertising alliance to rival Google, others, BI says
The Guardian, CNN International, The Financial Times , Reuters (TRI) and The Economist are forming an advertising alliance, called Pangaea, in hopes of rivaling Google (GOOG), Facebook (FB), Twitter (TWTR), and LinkedIn (LNKD), reports Business Insider UK. The Financial Times is owned by Pearson (PSO), The Economist Group is 50% owned by Pearson via The Financial Times, and CNN is owned by Time Warner (TWX). Reference Link
March 18, 2015
17:14 EDTGALTGalectin submitted request for SPA with clinical protocol for GR-MD-02 trial
"I am pleased with our many accomplishments during 2014 as we continue to advance programs with GR-MD-02 for the treatment of nonalcoholic steatohepatitis, NASH, with advanced fibrosis. We completed a successful Phase 1 clinical trial and announced final data in January 2015 that were supportive of our plans to begin a Phase 2 program with GR-MD-02 in advanced fatty liver disease, or NASH with fibrosis and cirrhosis," said Peter G. Traber, M.D., president, CEO and chief medical officer of Galectin Therapeutics. "As announced last month, we submitted the Phase 2 clinical trial protocol to the U.S. Food and Drug Administration, FDA, to evaluate the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis, the primary endpoint being to determine the change in the hepatic venous pressure gradient, HVPG, as compared with placebo. The FDA has indicated that HVPG may serve as a surrogate primary endpoint for NASH cirrhosis. We submitted a request for a Special Protocol Assessment with the clinical protocol for this trial. Additionally, we are planning to conduct a separate, shorter Phase 2 trial in NASH patients with advanced fibrosis. We expect to begin enrolling patients in both trials during the second quarter of 2015."
17:08 EDTGALTGalectin Therapeutics reports FY14 EPS (78c), consensus (77c)
As of December 31, the company had $29.1M of non-restricted cash and cash equivalents available to fund future operations. In January and February of 2015, the company received $4.1M in net proceeds from the issuance of common shares through its At-the-Market stock issuance program. The company believes that cash on hand of $29.7M as of March 13, is sufficient to fund its operations and research and development activities through September 30, 2016.
09:20 EDTGPROComplaints against police fell after body cameras added, Channel 10 says
Subscribe for More Information
06:03 EDTGPROStocks with implied volatility below IV index mean; CYBR GRPO
Subscribe for More Information
March 17, 2015
11:36 EDTGPROGoPro Channel app tops 1M downloads on Xbox platform
GoPro (GPRO) announced that The GoPro Channel app has been downloaded over 1M times on the Xbox video game and entertainment system from Microsoft (MSFT). Additionally, users are watching an average of 25 minutes of GoPro videos during each viewing session. The GoPro Channel allows Xbox members worldwide to stream GoPro content on-demand, share favorite videos, and purchase cameras and accessories directly through the console.
10:13 EDTSGMSOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTLNKDOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aimco (AIV) initiated with an Outperform at RW Baird... Alnylam (ALNY) initiated with a Buy at Janney Capital... American Campus (ACC) initiated with a Neutral at RW Baird... AvalonBay (AVB) initiated with a Neutral at RW Baird... BE Aerospace (BEAV) initiated with a Buy at CRT Capital... BlackRock (BLK) initiated with a Buy at Argus... Camden Property (CPT) initiated with an Outperform at RW Baird... CarMax (KMX) initiated with a Buy at Evercore ISI... Central Pacific (CPF) initiated with a Neutral at Macquarie... Cognex (CGNX) initiated with a Buy at Northcoast... Education Realty (EDR) initiated with a Neutral at RW Baird... EnerSys (ENS) initiated with an Overweight at Stephens... Equity Lifestyle (ELS) initiated with an Outperform at RW Baird... Equity Residential (EQR) initiated with a Neutral at RW Baird... Essex Property Trust (ESS) initiated with a Neutral at RW Baird... Facebook (FB) initiated with a Buy at Brean Capital... Intercept (ICPT) initiated with a Hold at MLV & Co.... Isis Pharmaceuticals (ISIS) initiated with a Neutral at Janney Capital... LinkedIn (LNKD) initiated with a Sell at Brean Capital... Mid-America Apartment (MAA) initiated with an Outperform at RW Baird... NetSuite (N) initiated with a Hold at Brean Capital... Paycom (PAYC) initiated with a Buy at Brean Capital... Platform Specialty Products (PAH) initiated with a Buy at UBS... Post Properties (PPS) initiated with a Neutral at RW Baird... Salesforce.com (CRM) initiated with a Hold at Brean Capital... ServiceNow (NOW) initiated with a Buy at Brean Capital... Snap-On (SNA) initiated with a Buy at Northcoast... Sun Communities (SUI) initiated with a Neutral at RW Baird... Twitter (TWTR) initiated with a Buy at Brean Capital... UDR, Inc. (UDR) initiated with an Outperform at RW Baird... Workday (WDAY) initiated with a Hold at Brean Capital... Xplore Technologies (XPLR) initiated with a Buy at Roth Capital... Yahoo (YHOO) initiated with a Hold at Argus.
March 16, 2015
17:13 EDTGALTGalectin Therapeutics files form to delay 10-K
Galectin Therapeutics is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the period ended December 31. Because the company was previously a smaller reporting company, this is the first time the company must obtain an audit of its internal control over financial reporting. As a result, additional time is needed for the company to provide its independent auditors with information necessary to complete the audit of the company’s internal control over financial reporting. The company anticipates that its Form 10-K will be filed within the prescribed extension period in accordance with Rule 12b-25(b).
16:18 EDTLNKDFollow-up: LinkedIn initiated with a Sell at Brean Capital
As previously reported, Brean Murray initiated Linkedin with a Sell and $208 price target. The firm believes expectations for Sales Navigator are too high and core site "browsability" is lacking.
16:14 EDTLNKDLinkedIn initiated with a Sell at Brean Capital
Subscribe for More Information
11:01 EDTLNKDLinkedIn acquires Careerify, terms not disclosed
Subscribe for More Information
10:50 EDTLNKDKing Digital seen benefiting from user base larger than Twitter, LinkedIn
Subscribe for More Information
10:46 EDTPGProcter & Gamble weighs deal for beauty brands, Bloomberg reports
Subscribe for More Information
10:40 EDTPGProcter & Gamble weighs single deal for beauty brands, Bloomberg says
Subscribe for More Information
10:35 EDTGPROGoPro falls, levels to watch
Subscribe for More Information
10:14 EDTSGMSOptions with decreasing implied volatility
Options with decreasing implied volatility: EXPR ULTA SGMS QIHU BKS PAY URBN AGN AGNC
06:16 EDTPGWal-Mart to sell Tide rival Persil in stores, WSJ reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use